Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 3.3%

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Rating)’s stock price traded down 3.3% during trading on Friday . The stock traded as low as $11.75 and last traded at $12.00. 458 shares changed hands during trading, a decline of 100% from the average session volume of 164,250 shares. The stock had previously closed at $12.41.

Several equities research analysts recently commented on the company. Piper Sandler assumed coverage on Alpha Tau Medical in a report on Friday, April 8th. They set an “overweight” rating and a $19.00 target price on the stock. Cantor Fitzgerald assumed coverage on Alpha Tau Medical in a report on Thursday, April 14th. They set an “overweight” rating and a $20.00 target price on the stock. Finally, Citigroup assumed coverage on Alpha Tau Medical in a report on Monday, April 4th. They set a “buy” rating and a $21.00 target price on the stock.

The business has a 50-day moving average of $8.28.

Alpha Tau Medical (NASDAQ:DRTS – Get Rating) last posted its quarterly earnings results on Thursday, May 26th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.47). Equities analysts expect that Alpha Tau Medical Ltd. will post -0.76 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of DRTS. Clear Street LLC acquired a new position in Alpha Tau Medical in the first quarter worth approximately $30,000. Penserra Capital Management LLC purchased a new position in Alpha Tau Medical during the 1st quarter worth approximately $40,000. Finally, Ergoteles LLC purchased a new position in Alpha Tau Medical during the 1st quarter worth approximately $146,000. Hedge funds and other institutional investors own 81.91% of the company’s stock.

Alpha Tau Medical Company Profile (NASDAQ:DRTS)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

See Also